BETASTEM THERAPUETICS, INC.

Biotech · Defunct

Autologous CD34+ stem cells modified with TGF-β inhibition via antisense morpholino oligomers for retinal vascular repair

Grants
$923K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Autologous TGFB1 Modified CD34+ Stem Cells for Repair of Diabetic Macular Edema and Macular Ischemia$461,417
Federal grantDepartment of Health and Human Services · Phase I · Autologous TGFB Modified CD Stem Cells for Repair of Diabetic Macular Edema and Macular Ischemia$461,417
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2865Aspect Biosystems——
2866KOMMODO THERAPEUTICS LLC——
2867VIVOSPHERE LLC——
2868BETASTEM THERAPUETICS, INC.——
2869NUTRIWYO, LLC——
2870Nutcracker Therapeutics—$172M
2871REDVAULT BIOSCIENCES LP——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.